# A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm

Source: https://onco.cc/trials/nct07802821/  
OnCo record `nct07802821` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of QLC5508, QL2107, tislelizumab, carboplatin and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07802821 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 556 participants, started 2026-10-15 and due to reach its primary completion in 2029-03-15. Interventions recorded: QLC5508; QL2107; Tislelizumab; Carboplatin; Cisplatin; Etoposide. Conditions listed: Extensive-stage Small Cell Lung Cancer. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "Participants with histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) per the Veterans Administration Lung Cancer Study Group (VALG) staging system". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07802821
- Phase: 3
- Setting: A Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 556

## Sources

- ClinicalTrials.gov NCT07802821: https://clinicaltrials.gov/study/NCT07802821

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [QL2107](https://onco.cc/drugs/ql2107/), [QLC5508](https://onco.cc/drugs/qlc5508/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07802821.json